NOG-MHC I/II-2 KO小鼠, NOG-MHC I/II-2 KO Mice (NOG-dKO) - 维通利华

产品服务 > 实验动物模型 > 查找动物模型品系

NOG-MHC I/II-2 KO Mice (NOG-dKO)

品系代码：

411

专业名称：

NOD.Cg-Prkdc^scidIl2rg^tm1SugB2m^em1TacH2-Ab1^tm1Doi/JicCrl

小鼠,免疫缺陷模型免疫学,肿瘤学同类系,免疫缺陷

【CIEM正式授权】PBMC人源化模型构建、肿瘤免疫治疗、T细胞免疫功能研究、GVHD相关研究、免疫检查点抑制剂研究。

品系来源

应用特性

价格规格

生长曲线

应用文献

品系来源

NOG-dKO(NOG-MHC I/II-2 KO)小鼠是由日本中央实验动物研究所(CIEM)的Mamoru Ito博士培育而成。Mamoru Ito博士实验室利用CRISPR技术在NOG小鼠基础上敲除B2m和Ab1基因，培育出的双基因敲除模型。

* CIEM已将NOG-dKO在日本地区的名称更新为NOG-ΔMHC (NOG-Iab KO, B2m KO2)，但在中国地区维通利华仍沿用NOG-dKO名称，二者实际为同一品系，点击查看

【维通利华 - 中国大陆地区CIEM官方授权经销商 - NOG模型系列】

✈ 2019年、2020年，维通利华从CIEM引入该品系核心群。

☑ 拓展阅读：不同NOG衍生品系的特点与应用场景解析

科研必备：不同NOG衍生品系的特点与应用场景解析

应用特性

研究用途：

免疫系统重建(huPBMC-NOG-dKO) （huPBMC-NOG-dKO现货提供）
肿瘤免疫治疗
CAR-T药效评估：NOG-dKO小鼠可降低CAR-T细胞在临床前动物实验中的GvHD反应，助于药效评估。
T细胞免疫功能研究
GVHD研究

特性：

毛色：白化

除了NOG小鼠的特性外，还具备以下特性：

MHC Ⅰ/Ⅱ缺失；
hPBMC移植后，窗口期可延长至12周；
hPBMC移植后，GVHD发生延迟

huPBMC-NOG-dKO

➢制备周期短，成本低

➢T细胞重建

➢GvHD反应弱，研究周期可长达12周

➢靶点在T细胞的肿瘤免疫治疗：双特异性抗体、免疫检查点抑制剂

特别提示:

NOG-dKO小鼠的huPBMC免疫系统重建模型，由于敲除了MHC I/II 类分子，huPBMC注射后GVHD反应非常弱，一方面提高了研究周期，可达12周。另一方面由于没有PBMC Xeno-GVHD造成的非特异性T细胞扩增，能更精准地评判药物的抗肿瘤活性。

同时由于NOG-dKO小鼠PBMC注射后GVHD反应非常弱，不会引起由于GVHD反应而导致的T细胞扩增，从而重建率要低于NOG小鼠，故注射剂量要稍高。日本CIEM建议移植剂量为5-10*10^6，维通利华对外提供的模型注射剂量在5-7*10^6范围内，不同的donor来源会有差异，供参考。

价格规格

品系代码	品系名称	日/周龄	性别	VAF/SPF级	Elite/SPF级
411	NOG-dKO	1-8周	雌		1050

*以上规格与价格自2025年1月1日至2025年12月31日有效。

生长曲线

NOG-MHC I/II-2 KO Mice (NOG-dKO)

应用文献

NOG dKO Publications

Authors	Year	Paper Title	Keywords
Huan Wei, et al.	2025	Mogat1 drives metabolic adaptations to evade immune surveillance	T-cell infiltration，Mogat1, PD-1, MDA-MB-231
Tomoatsu Ikeya, et al.	2025	Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHCdouble knockout NOG mouse model	Immune checkpoint inhibitor, PD-1/PD-L1, Triple-negative breast cancer, NOG mouse, Humanized mouse
Jiayi Shen, et al.	2024	Low Immunogenicity of Keratinocytes Derived from Human Embryonic Stem Cells	keratinocytes, embryonic stem cells, differentiation, allograft rejection, immunogenicity
Yoshikawa, et al.	2024	Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells	chimeric cytokine receptor G6/7R， IL-6, CAR-T
Yun Huang, et al.	2024	Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity	B7H3，monoclonal antibody, Ab-82, cytotoxic T lymphocyte
Keisuke Ohta, et al.	2024	Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer	CAR-T, IL7/CCL19, EGFR, Glioblastoma, Pancreatic Cancer,
Ryu Matsumoto, MD, et al.	2024	CD8+ T cell-mediated rejection of allogenic human-induced pluripotent stem cell-derived cardiomyocyte sheets in human PBMC-transferred NOG MHC double knockout mice	HiPS-CMs, CD8+ T cell-mediated rejection, NOG MHC double knockout mice, xeno-GVHD, iPS
Guo et al.	2024	A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML	CD36, AML, MV4-11, T cell, immunosuppression
Zhu W, et al.	2024	OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS–STING pathway to mediate GBM immune escape	OMA1. HSPA9, cGAS–STING pathway, GBM，PD-1, CD8+T
Shen, J, et al.	2024	Low Immunogenicity of Keratinocytes Derived from Human Embryonic Stem Cells	keratinocytes; embryonic stem cells; differentiation; allograft rejection; immunogenicity
Hirofumi Nakano, et al.	2024	Fatty Acids Play a Critical Role in Mitochondrial Oxidative Phosphorylation in Effector T Cells in Graft-versus-Host Disease	Fatty Acids, GvHD, MHC-/- NOG , MHC+/+ NOG , CD8+T, CD4+T
Yi Ouyang, et al.	2023	FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation	FGFR3, duvelisib，bladder cancer cells, T cell, macrophage
Takahiro Sasaki, et al.	2023	Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model	CAR-T cell, chemokine, cytokine, ganglioside, solid cancers
Zhou C, et al.	2023	Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma	Schlafen 11; tumor-associated macrophages; immune checkpoint inhibitors; serum biomarker
Zhuang Chen, et al.	2023	YTHDF2-mediated circYAP1 drives immune escape and cancer progression through activating YAP1/TCF4-PD-L1 axis	circYAP1, YAP1/TCF4, PD-L1, CD8+ T, HCT116
Y. Wang, et al.	2023	PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma	PRMT3, SGC707, endometrial cancer (EC), PD-1, PBMC-NOG-dKO
Yasuto Akiyama, et al.	2022	Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding	SCC-3, PD-1/PD-L1，small chemical compound，PBMCs
Bo Wang, et al.	2021	Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells	CAR-T, iPSC-derived T cells, CD20, B-lymphoblastoid cell line
Takeshi Watanable	2021	human-type artificial lymphoid tissues induce antigen-specific immune responses upon antigen stimulation	artificial lymphoid tissues (aLTs), immunotherapy
Ling Yin, et al.	2020	Humanized mouse model: a review on preclinical applications for cancer immunotherapy	humanized mouse model, cancer, immunotherapy
Akira Iizuka, et al.	2019	A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer	bsAbs, breast cancer, PBMCs, humanized
Tadashi Ashizawa, et al.	2019	Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse	PBMCs,PD-1/PD-L1 binding inhibitor, SCC-3,lympoma, humanized
Tadashi Ashizawa, et al.	2019	Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status	pancreatic cancer,immune checkpoint blockade(ICB), PD-1, mAbs, STAT3 inhibitor, humanized
Yasufumi Kawasaki, et al.	2019	Alloreactive T Cells Display a Distinct Chemokine Profile in Response to Conditioning in Xenogeneic GVHD Models	GvHD, CCR5 antagonist, pan T cell, humanized
Satoshi Aono, et al.	2018	Immunological responses against hepatitis B virus in human peripheral blood mononuclear cell-engrafted mice	Hepatitis B virus, vaccine, PBMCs, humanized
Tadashi Ashizawa, et al.	2017	Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse	PBMCs, glioblastoma, lymphoma, PD-1, mAbs, humanized
Tomonori Yaguchi, et al.	2017	Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses	ACT, PBMCs, vaccine, humanized
Yasuto Akiyama, et al.	2017	The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line	PBMCs, STAT3 inhibitor,TIL, TMZ-resistant glioblastoma, humanized
Tomonori Yaguchi, et al.	2013	MHC class I/II deficient NOG mice are useful for analysis of human T/B cell responses for human tumor immunology research	PBMCs, humanized